Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 6/2009

01-11-2009

IL-2, IFN-γ, and IL-12 Gene Polymorphisms and Susceptibility to Multiple Sclerosis

Authors: Mohammad Ali Shokrgozar, Sheila Sarial, Aliakbar Amirzargar, Fazel Shokri, Nima Rezaei, Zohreh Arjang, Jalaledin Radfar, Manijeh Yousefi-behzadi, Mohammad Ali Sahraian, Jamshid Lotfi

Published in: Journal of Clinical Immunology | Issue 6/2009

Login to get access

Abstract

Background

Multiple sclerosis (MS) is a multifactorial disease. Positive genetic background could predispose individuals to this chronic disabling disease. In order to investigate the role of some proinflammatory cytokines (interleukin (IL)-2, IL-12, and interferon-gamma (IFN-γ)) as a risk factor for MS, this study was performed.

Methods

Two hundred and eleven patients with relapsing-remitting form of MS were enrolled in this study and compared with 359 healthy individuals. Using polymerase chain reaction based on sequence-specific primer method, the cytokine genes were amplified, and alleles and genotypes were detected on gel electrophoresis.

Results

Significant increases for IFN-γ AT (+874) genotype (54.5% vs. 37.8%, p = 0.0002) and IL-12 AA (−1188) genotype (60.8% vs. 49.7%, p = 0.014) were found in MS patients in comparison with healthy controls. A significant decrease in IFN-γ TT (+874) genotype (17.7% vs. 27.5%, p = 0.01) and IL-12 CA (–1188) genotype (30.9% vs. 45%, p = 0.001) in MS patients was also detected. No significant differences of IL-2 G/T (−330) and IL-2 G/T (+166) in alleles and genotypes were observed between MS patients and normal subjects.

Conclusions

It could be suggested that the genetic variation in IL-12 A/C (−1188) and IFN-γ A/T (+874) cytokine genes could be risk factors for MS patients.
Literature
1.
Grigoriadis N, Grigoriadis S, Polyzoidou E, Milonas I, Karussis D. Neuroinflammation in multiple sclerosis: evidence for autoimmune dysregulation, not simple autoimmune reaction. Clin Neurol Neurosurg. 2006;108:241–4.CrossRefPubMed
2.
Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999;1:3–19.CrossRefPubMed
3.
Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun. 2001;2:61–70.CrossRefPubMed
4.
Bidwell JL, Wood NA, Morse HR, Olomolaiye OO, Keen LJ, Laundy GJ. Human cytokine gene nucleotide sequence alignments: supplement 1. Eur J Immunogenet. 1999;26:135–223.CrossRefPubMed
5.
Hollegaard MV, Bidwell JL. Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun. 2006;7:269–76.CrossRefPubMed
6.
Amirzargar AA, Bagheri M, Ghavamzadeh A, Alimoghadam K, Khosravi F, Rezaei N, et al. Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia. Int J Immunogenet. 2005;32:167–71.CrossRefPubMed
7.
Amirzargar AA, Rezaei N, Jabbari H, Danesh AA, Khosravi F, Hajabdolbaghi M, et al. Cytokine single nucleotide polymorphisms in Iranian patients with pulmonary tuberculosis. Eur Cytokine Netw. 2006;17:84–9.PubMed
8.
Mahdaviani SA, Rezaei N, Moradi B, Dorkhosh S, Amirzargar AA, Movahedi M. Proinflammatory cytokine gene polymorphisms among Iranian patients with asthma. J Clin Immunol. 2009;29:57–62.CrossRefPubMed
9.
Rezaei N, Amirzargar AA, Shakiba Y, Mahmoudi M, Moradi B, Aghamohammadi A. Proinflammatory cytokine gene single nucleotide polymorphisms in common variable immunodeficiency. Clin Exp Immunol. 2009;155:21–7.CrossRefPubMed
10.
Amirzargar A, Mytilineos J, Yousefipour A, Farjadian S, Scherer S, Opelz G, et al. HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. Eur J Immunogenet. 1998;25:297–301.CrossRefPubMed
11.
Amirzargar AA, Tabasi A, Khosravi F, Kheradvar A, Rezaei N, Naroueynejad M, et al. Optic neuritis, multiple sclerosis and human leukocyte antigen: results of a 4-year follow-up study. Eur J Neurol. 2005;12:25–30.CrossRefPubMed
12.
Amirzargar A, Khosravi F, Dianat S, Hushmand F, Maryousef P, Foroushani AR, et al. Profile of cytokine gene polymorphisms in Iranian multiple sclerosis patients. Mult Scler. 2007;13:253–5.CrossRefPubMed
13.
Sarial S, Shokrgozar MA, Amirzargar A, Shokri F, Radfar J, Zohrevand P, et al. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol. 2008;7:37–40.PubMed
14.
Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851–62.CrossRefPubMed
15.
Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, Pelletier D, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet. 2009;18:2078–90.CrossRefPubMed
16.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.CrossRefPubMed
17.
Amirzargar AA, Naroueynejad M, Khosravi F, Dianat S, Rezaei N, Mytilineos J, et al. Cytokine single nucleotide polymorphisms in Iranian populations. Eur Cytokine Netw. 2008;19:104–12.PubMed
18.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.CrossRefPubMed
19.
Corcione A, Aloisi F, Serafini B, Capello E, Mancardi GL, Pistoia V, et al. B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmun Rev. 2005;4:549–54.CrossRefPubMed
20.
Hofstetter HH, Toyka KV, Gold R. Permanent effector phenotype of neuroantigen-specific T cells acquired in the central nervous system during experimental allergic encephalomyelitis. Neurosci Lett. 2006;391:127–30.CrossRefPubMed
21.
Kikuchi S, Niino M, Fukazawa T, Yabe I, Tashiro K. An assessment of the association between IL-2 gene polymorphisms and Japanese patients with multiple sclerosis. J Neurol Sci. 2002;205:47–50.CrossRefPubMed
22.
Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994;179:973–84.CrossRefPubMed
23.
Matesanz F, Delgado C, Fresno M, Alcina A. Allelic selection of human IL-2 gene. Eur J Immunol. 2000;30:3516–21.CrossRefPubMed
24.
Matesanz F, Fedetz M, Collado-Romero M, Fernandez O, Guerrero M, Delgado C, et al. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J Neuroimmunol. 2001;119:101–5.CrossRefPubMed
25.
Matesanz F, Fedetz M, Leyva L, Delgado C, Fernandez O, Alcina A. Effects of the multiple sclerosis associated −330 promoter polymorphism in IL2 allelic expression. J Neuroimmunol. 2004;148:212–7.CrossRefPubMed
26.
Matesanz F, Fernandez O, Alcina A. Genomewide study of multiple sclerosis. N Engl J Med. 2007;357:2200. author reply-1.PubMed
27.
Lees JR, Cross AH. A little stress is good: IFN-gamma, demyelination, and multiple sclerosis. J Clin Invest. 2007;117:297–9.CrossRefPubMed
28.
Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther. 2005;106:163–77.CrossRefPubMed
29.
Issazadeh S, Ljungdahl A, Hojeberg B, Mustafa M, Olsson T. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor. J Neuroimmunol. 1995;61:205–12.CrossRefPubMed
30.
Issazadeh S, Mustafa M, Ljungdahl A, Hojeberg B, Dagerlind A, Elde R, et al. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res. 1995;40:579–90.CrossRefPubMed
31.
Kantarci OH, Hebrink DD, Schaefer-Klein J, Sun Y, Achenbach S, Atkinson EJ, et al. Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression. Arch Neurol. 2008;65:349–57.CrossRefPubMed
32.
Wansen K, Pastinen T, Kuokkanen S, Wikstrom J, Palo J, Peltonen L, et al. Immune system genes in multiple sclerosis: genetic association and linkage analyses on TCR beta, IGH, IFN-gamma and IL-1ra/IL-1 beta loci. J Neuroimmunol. 1997;79:29–36.CrossRefPubMed
33.
Mihailova S, Ivanova M, Mihaylova A, Quin L, Mikova O, Naumova E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol. 2005;168:138–43.CrossRefPubMed
34.
Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet. 1999;26:1–3.CrossRefPubMed
35.
Kang BY, Kim E, Kim TS. Regulatory mechanisms and their therapeutic implications of interleukin-12 production in immune cells. Cell Signal. 2005;17:665–73.CrossRefPubMed
36.
Campbell IL, Stalder AK, Akwa Y, Pagenstecher A, Asensio VC. Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation. 1998;5:126–35.CrossRefPubMed
37.
Alifirova VM, Orlova I, Babenko SA, Rudko AA, Puzyrev VP. The 1188 A/C ILI2B gene polymorphism in patients with multiple sclerosis and in healthy subjects of Tomsk region. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;3:130–5.
38.
van Veen T, Crusius JB, Schrijver HM, Bouma G, Killestein J, van Winsen L, et al. Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis. Ann Neur. 2001;50(2):275.CrossRef
39.
Seegers D, Zwiers A, Strober W, Pena AS, Bouma G. A TaqI polymorphism in the 3′UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun. 2002;3:419–23.CrossRefPubMed
40.
Hall MA, McGlinn E, Coakley G, Fisher SA, Boki K, Middleton D, et al. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun. 2000;1:219–24.CrossRefPubMed
41.
Martinez A, Varade J, Marquez A, Cenit MC, Espino L, Perdigones N, et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum. 2008;58:2598–602.CrossRefPubMed
Metadata
Title
IL-2, IFN-γ, and IL-12 Gene Polymorphisms and Susceptibility to Multiple Sclerosis
Authors
Mohammad Ali Shokrgozar
Sheila Sarial
Aliakbar Amirzargar
Fazel Shokri
Nima Rezaei
Zohreh Arjang
Jalaledin Radfar
Manijeh Yousefi-behzadi
Mohammad Ali Sahraian
Jamshid Lotfi
Publication date
01-11-2009
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 6/2009
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-009-9310-z

Other articles of this Issue 6/2009

Journal of Clinical Immunology 6/2009 Go to the issue

ReviewPaper

Immunological Challenges of Cardiac Transplantation: The need for Better Animal Models to Answer Current Clinical Questions

OriginalPaper

Novel Mutations in TACI (TNFRSF13B) Causing Common Variable Immunodeficiency

OriginalPaper

Clinical and Laboratory Findings in Hyper-IgM Syndrome with Novel CD40L and AICDA Mutations

OriginalPaper

Tissue Transglutaminase Can Be Involved in Airway Inflammation of Toluene Diisocyanate-Induced Occupational Asthma

OriginalPaper

Impairment of Monocyte-derived Dendritic Cells in Idiopathic Pulmonary Arterial Hypertension

OriginalPaper

Autoimmunity, Infectious Immunity, and Atherosclerosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits